WX-UK1

DRACPC ID  DRACPC0085

Active Ingredients   WX-UK1

Description  A 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play a key role in metastasis and primary tumor growth of breast, gastric, colon cancer, and various other solid tumors.

Synonyms  WX UK1; WX-UK1

Type  Small Molecule

Disease  Solid tumors

Classification

  

Amino acid and derivative

Structure Information


Molecular Formula  C32H48ClN5O5S

Molecular Weight  649.3

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[2,4,6-tris(propan-2-yl)benzenesulfonamido]propanoyl]piperazine-1-carboxylate hydrochloride

InChI  InChI=1S/C32H47N5O5S.ClH/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7;/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34);1H/t28-;/m0./s1

InChI_Key FMHIVIJVVYYSRN-JCOPYZAKSA-N

SMILES  O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(N)=N)=C3)=O)CC1)OCC.[H]Cl

External Codes


PubChem CID  9939426

DrugBank Accession Number  DB05476

NCI Thesaurus Code  Not available

UNII  UJ925Q0P3B   GSRS

CAS  255374-84-6



Drug approval


Drug indication
    Investigated for use/treatment in solid tumors.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00083525 Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies Advanced Malignancies Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.